Scotiabank Predicts OR Royalties’ FY2027 Earnings (NYSE:OR)

OR Royalties Inc. (NYSE:OR) – Investment analysts at Scotiabank lowered their FY2027 earnings estimates for shares of OR Royalties in a research report issued on Wednesday, July 15th. Scotiabank analyst T. Jakusconek now anticipates that the basic materials company will post earnings per share of $1.21 for the year, down from their previous estimate of $1.31. Scotiabank has a “Sector Perform” rating and a $42.00 price target on the stock. The consensus estimate for OR Royalties’ current full-year earnings is $1.35 per share.

A number of other research analysts have also weighed in on OR. Weiss Ratings lowered OR Royalties from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 4th. Jefferies Financial Group cut their price target on OR Royalties from $40.00 to $34.00 and set a “hold” rating for the company in a report on Monday, July 6th. Zacks Research cut shares of OR Royalties from a “hold” rating to a “strong sell” rating in a research report on Monday. Wall Street Zen downgraded shares of OR Royalties from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Royal Bank Of Canada dropped their price objective on shares of OR Royalties from $50.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.50.

OR Royalties Stock Down 2.8%

OR opened at $28.01 on Friday. OR Royalties has a 12-month low of $26.86 and a 12-month high of $48.06. The stock has a market cap of $5.25 billion, a price-to-earnings ratio of 20.90 and a beta of 0.74. The business has a 50 day moving average of $33.92 and a 200-day moving average of $38.14.

OR Royalties (NYSE:OR) last announced its quarterly earnings results on Wednesday, May 6th. The basic materials company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The firm had revenue of $102.83 million for the quarter, compared to the consensus estimate of $103.27 million. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%.

Hedge Funds Weigh In On OR Royalties

Several institutional investors and hedge funds have recently modified their holdings of the business. State of Wyoming bought a new position in OR Royalties during the first quarter worth about $28,000. FIL Ltd bought a new stake in OR Royalties in the 4th quarter valued at about $29,000. Grove Bank & Trust bought a new stake in OR Royalties in the 2nd quarter valued at about $32,000. Assetmark Inc. acquired a new position in shares of OR Royalties during the 4th quarter worth approximately $36,000. Finally, Banque Cantonale Vaudoise acquired a new position in shares of OR Royalties during the 1st quarter worth approximately $37,000. 68.52% of the stock is currently owned by institutional investors and hedge funds.

OR Royalties Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 15th. Stockholders of record on Tuesday, June 30th were given a $0.065 dividend. The ex-dividend date of this dividend was Tuesday, June 30th. This is a boost from OR Royalties’s previous quarterly dividend of $0.06. This represents a $0.26 dividend on an annualized basis and a dividend yield of 0.9%. OR Royalties’s dividend payout ratio (DPR) is presently 18.66%.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.